Conclusion
In conclusion, our study demonstrated the preliminary efficacy and manageable safety of IP/IC plus camrelizumab followed by maintenance camrelizumab plus apatinib in untreated ES-SCLC, compared with EP/EC plus PD-L1 inhibitor. The occurrence of irAEs was associated with a longer PFS, which may be a potential prognostic factor for patients treated with ICIs.